CRLX101

Known as: Cyclodextrin-Based Polymer-Camptothecin CRLX101 
A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
02420112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Nanoparticle-based therapeutics are being used to treat patients with solid tumors. Whereas nanoparticles have been shown to… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
VEGF pathway-targeting antiangiogenic drugs, such as bevacizumab, when combined with chemotherapy have changed clinical practice… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
PURPOSE Increased tumor hypoxia and hence elevated hypoxia-inducible factor-1α (HIF1α) is thought to limit the efficacy of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Antiangiogenic therapies inhibit the development of new tumor blood vessels, thereby blocking tumor growth. Despite the advances… (More)
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
2014
2014
CRLX101 is a nanopharmaceutical consisting of cyclodextrin-based polymer molecule and camptothecin. The CRLX101 nanoparticle is… (More)
Is this relevant?
2013
2013
PURPOSE Targeted nanotherapies are being developed to improve tumor drug delivery and enhance therapeutic response. Techniques… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 5
  • figure 5
Is this relevant?
2012
2012
UNLABELLED Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Camptothecin (CPT) is a potent broad-spectrum anticancer agent that acts through inhibition of topoisomerase 1. Clinical… (More)
Is this relevant?
2011
2011
CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by… (More)
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?